- 點擊【立即啟動】(藍框處)打開 Microsoft Edge
Oneness has submitted medical device registration application for Bonvadis to the Egyptian Drug Authority (EDA).
Oneness announces the information about the investor's conference of 2023 Q3.
The board of directors of the Company approved removal of the noncompete clause for managers.
Oneness has submitted a 510(k) application to the U.S. FDA to expand the intended patient population and add multiple chronic wound indications for Bonvadis.
A Russian patent titled “TREATING IGE-MEDIATED ALLERGIC DISEASES” on FB825 was granted.
The Company’s 2023 Q2 consolidated financial statements have been approved by the Board of Directors
Oneness was notified today that Bonvadis, the wound care topical cream has obtained import license in South Africa.
Oneness was notified today that Bonvadis, the wound care topical cream has submitted a registration application to the Drug Regulatory Authority of Pakistan (DRAP).
SNS812, a broad-spectrum siRNA for COVID-19 infection, co-developed by Oneness & Microbio (Shanghai) has been agreed by US FDA to proceed with Phase 2 clinical trial.
Oneness Biotech Co., Ltd. receives a European patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101).
Fespixon cream has been approved to be reimbursed by the National Health Insurance
FESPIXON, the new drug in treatment of diabetic foot ulcers has been approved by Malaysia NPRA
Clarification on the media report with regards to the registration approval on Fespixon by Malaysia MOH
Oneness was notified today that Bonvadis, the wound care topical cream has submitted medical device registration to South African Health Products Regulatory Authority.
SNS812, a broad-spectrum siRNA co-developed by Oneness and Microbio (Shanghai) to treat SARS-CoV-2 infection, was greenlighted by TFDA to proceed with a Ph2 study